As one who probably has to accept a good deal of responsibility for introducing the idea that thermogenesis, particularly that arising from sympathetic activation of brown fat, plays a major role in the regulation of energy balance, 1 I was very pleased to be asked to chair one of the sessions in this symposium on uncoupling proteins. However, I was a little surprised when Claude Bouchard asked me, a physiologist, to oversee a session devoted to genetic and molecular aspects, but then realised that he was hoping that I would summarise the session in a way that was comprehensible to those with a similar elementary and naive understanding of genetics and molecular biology as my own. I trust this is borne out by what follows, but also hope that some of the issues highlighted are of value to those with a more esoteric knowledge of the subcellular world.
The ®rst presentation in this session was on UCP1 by Kozak and Koza, and promised to be particularly relevant to those interested in the sympathetic control of diet-induced thermogenesis (DIT) and the blunted, or defective activity of this system seen in most models of obesity. However, given the enormous amount of work that has been directed to the study of this unique brown adipose tissue (BAT) mitochondrial protein since it was ®rst discovered over 20 y ago, 2 one wondered whether there was anything new to say about it. Leslie Kozak's presentation soon revealed that this was far from the case, and his description of various genetic models with over or under-expression of UCP1 showed that the effects of these manipulations on overall energy balance was complex and far from predictable. Kozak points out several pitfalls in sticking to simplistic interpretations, and particularly highlights the importance of genetic background in determining whether or not manipulating the UCP1 gene has an impact on adiposity. Genetic background is just one of the problems encountered when extrapolating from studies at the molecular or cellular level to what happens in the whole animal. Another is that manipulations resulting in an increase in UCP1-gene expression (mRNA), or even in mitochondrial UCP protein content, do not necessarily result in an increase in thermogenesis. A well-known example of this is the cold-adapted rat which, when brought into a warm laboratory, will retain a high mitochondrial concentration of UCP1 for several days 3 even though it is not exhibiting any nonshivering thermogenesis (NST). This is because BAT activation by the sympathetic nervous system (SNS) switches off as soon as the cold stimulus is removed. Similarly, rats treated with thiozolidinediones (for example, ciglitazone) do not exhibit increased levels of thermogenesis, but do exhibit marked increases in BAT mitochondrial UCP1 Ð that is the drugs increase the thermogenic capacity of brown fat, but that capacity is not utilised unless BAT is activated by the SNS or b-adrenoceptor (bAR) agonists. 4 Further complications arise from the intimate relationship between thermoregulation and energy metabolism, and goes some way towards explaining the hyperphagia and obesity of the transgenic mouse bearing the UCP1-DTA toxigene that causes genetic ablation of BAT. When the animal is kept below thermoneutrality, its reduced capacity for NST causes it to overeat in an attempt to keep warm, but because of its reduced capacity for DIT the hyperphagia results in obesity. However, when reared in a warm, thermoneutral environment, the thermal drive to overeat has been removed and so the mouse does not become obese. Even this explanation is more than a little simplistic and needs some caveats, one being that it is probably the loss of brown adipocytes and other, compensatory thermogenic pathways rather than the reduction in UCP1 per se that is important. It has been suggested 5 that loss of a satiety factor normally secreted by BAT explains the hyperphagia of UCP-DTA mice, but neither this, nor the idea that hyperphagia is due to a hypothalamic lesion, can explain why intake is perfectly normal when these mice are housed at thermoneutrality and, in some cases, below thermoneutrality. 6 Kozak quite rightly points out that obesity is a complicated process, and another example where it is easy to make facile extrapolations is when people test thermogenic capacity using b 3 AR agonists and assume that the response will indicate how well or badly an animal responds to a dietary challenge, such as a high-fat diet. It has to be remembered that the b 3 AR agonist will by-pass completely all the normal neural and hormonal afferent, central and efferent mechanisms involved in the regulation of energy balance, and will be acting as a direct agonist of, possibly, just one effector (BAT) in that complex regulatory system. Another problem arises when trying to equate resistance to obesity with resistance to cold, since cold tolerance (that is, NST) can be severely compromised by small reductions in thermogenic capacity that have no effect at all on the relatively modest amount of DIT required to dissipate excess dietary energy to prevent obesity.
A somewhat disproportionate amount of time has been spent on UCP1 in this summary, but this has been deliberate in order to show the sort of problems we are facing with a protein which has been known and studied for over 20 y. This should give some idea of the problems that lie ahead when we come to consider the control and role of UCP2 and UCP3, which were not known to exist until just under two years ago. Nevertheless, as the contributions from Daniel Ricquier and Brad Lowell so eloquently demonstrated, we now have techniques available which will increase rapidly our knowledge and understanding of the genetics and molecular biology of these two new UCPs.
Taken together, the descriptions of UCP2 and UCP3 reveal some intriguing similarities between the two, but also some important differences. If anything, UCP3 is more closely related to UCP1 since its expression in humans is restricted to only one tissue Ð skeletal muscle (cf BAT for UCP1). UCP2, on the other hand, has an almost ubiquitous tissue expression that must raise serious questions about its potential role in adaptiveafacultive thermogenesis. Moreover, although both UCP2 and UCP3 exhibit uncoupling activity when expressed in yeast mitochondria, this has yet to be demonstrated in mammalian mitochondria. However, the degree of homology between UCP3 and UCP1 suggests that UCP3 is more likely to be a true uncoupling protein, but con®rma-tion of this, and the carrier functions proposed for UCP2, must be high on the list of current research priorities. Other important research aims will be to purify and reconstitute the two new mitochondrial proteins, particularly if the short transcript of the UCP3 gene results in a stable protein. Ligands and antibodies are required for functional and immunocytochemical investigations and, of course, transgenic models of over-expression, deletion and mutation will be needed to help describe and quantify the role in metabolism of these two mitochondrial proteins.
A feature of the three UCP presentations in this session was that, although they relied very heavily on genetic and molecular studies, the discussion almost inevitably centred around how these proteins affected physiological function. Therefore, one was already anticipating much of what was to be presented in the third and ®nal session of the conference. However, before that session, there were the two papers from Warden and Leibel on genetic aspects of the UCPs in humans, and unlike the previous speakers, they had little or nothing to say about physiological function. As Craig Warden was very keen to point out, this is because geneticists attempt to relate speci®c genes to certain traits irrespective of function Ð that is an established association between a UCP gene and obesity does not necessarily tell you if or how that gene causes obesity. What is clear from Warden's and Leibel's presentations is that, as with other linkage and association studies for other, similar genes (for example UCP1 and the b 3 AR gene), the in¯uence these genes might exert on various parameters of fatness or metabolism is going to be weak. Moreover, given the close linkage between the UCP2 and UCP3 genes on the human genome (6 kb separation) it is going to be very dif®cult to discriminate between the in¯uence on one from the other, although continued screening for variants in either or both will be helpful. While it is clearly necessary to carry out this genetic dissection' to determine the impact of individual genes on metabolism and obesity, it would seem that eventually we will be looking at a spectrum of genes associated with metabolism and thermogenesis (UCP1, UCP2, UCP3, b 3 AR, etc), and that a certain combination of variants affecting metabolism will be shown to have the strongest association with obesity or, perhaps more correctly, contribute to the susceptibility to obesity.
